Masimo Co. (NASDAQ:MASI) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Masimo Co. (NASDAQ:MASI) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $194.80.

A number of equities research analysts recently weighed in on MASI shares. Wells Fargo & Company increased their price target on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research note on Wednesday. Raymond James increased their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research report on Friday, December 27th. Piper Sandler lifted their target price on shares of Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price target (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday.

Masimo Stock Up 12.3 %

Masimo stock opened at $190.34 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company’s 50-day moving average is $172.56 and its 200-day moving average is $152.84. The firm has a market capitalization of $10.19 billion, a PE ratio of 131.27 and a beta of 1.02. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $191.10.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Sell-side analysts anticipate that Masimo will post 4.1 earnings per share for the current year.

Hedge Funds Weigh In On Masimo

A number of hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its holdings in shares of Masimo by 5,340.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,394 shares of the medical equipment provider’s stock worth $319,000 after purchasing an additional 2,350 shares during the period. State of Alaska Department of Revenue grew its position in Masimo by 7.2% during the third quarter. State of Alaska Department of Revenue now owns 5,139 shares of the medical equipment provider’s stock worth $685,000 after buying an additional 345 shares in the last quarter. SteelPeak Wealth LLC bought a new position in Masimo during the 3rd quarter worth $570,000. Roubaix Capital LLC raised its holdings in Masimo by 37.0% in the 3rd quarter. Roubaix Capital LLC now owns 34,041 shares of the medical equipment provider’s stock valued at $4,539,000 after acquiring an additional 9,202 shares in the last quarter. Finally, Malaga Cove Capital LLC bought a new stake in shares of Masimo during the 3rd quarter valued at $401,000. 85.96% of the stock is owned by institutional investors.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.